| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_841b6831a6533d33cf060363d10042f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f579de42604b8165d8ab59f55d093d61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_56f0b62c705cbdf649f82132bda21e9c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-475
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5044
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5091
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N5-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N5-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate |
2010-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af8e661e769f83a5e9b1f3338a1ad9f0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a80652553fb7fdec467c1f1e729efae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e538748e4be64170b49b93cd529ca780 |
| publicationDate |
2013-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2013323232-A1 |
| titleOfInvention |
Methods for the identification and treatment of patients sensitive to anti igf-1r inhbition therapy |
| abstract |
Disclosed herein are methods of stratifying a patient population into an IGF-1R inhibitor responder or resistant population comprising assaying a sample of cells derived from a patient to determine if a cell from the patient sample is sensitive to treatment with an IGF-1R inhibitor and selecting a patient for treatment with an IGF-1R inhibitor if the cells from the patient are determined to be sensitive. The determination is based upon either the expression levels of wild type LKB1 in the patient sample wherein a low level of expression of the protein or the gene encoding the biomarker protein is predictive of a favorable outcome to an IGF-1R targeted therapy or detecting the presence of a loss of function mutant LKB1 in the sample, wherein presence of the mutant is predictive of a favorable outcome. The presence of the mutant may be accompanied by determining the expression level of IGF-1R in the same sample, wherein a concomitant increase in the level of expression of IGF-1R in addition to detecting the presence of the mutant protein also predicts a favorable outcome to an IGF-1R targeted therapy. Methods of treating a patient are also provided. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113564249-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11576716-B2 |
| priorityDate |
2009-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |